| Record Information |
| Version |
3.5 |
| Creation Date |
2006-05-22 09:12:01 -0600 |
| Update Date |
2013-02-08 17:12:02 -0700 |
| HMDB ID |
HMDB02656 |
| Secondary Accession Numbers |
None |
| Metabolite Identification |
| Common Name |
Prostaglandin A1 |
| Description |
Prostaglandin A1 (PGA1, a prostaglandin characterized by a cyclopentenone structure) has a fundamental structure common to punaglandin and clavulone, the antitumor eicosanoids discovered in marine organisms such as corals. It is well established that PGA1, which exert potent antiviral activity in several DNA and RNA virus models, induce heat shock protein (hsp)70 syntheses through cycloheximide sensitive activation of heat shock transcription factor. Antitumor prostaglandins are actively incorporated through cell membrane and control gene expression. P53 (protein 53, is a transcription factor that regulates the cell cycle and functions as a tumor suppressor) independent expression of p21 (also known as cyclin-dependent kinase inhibitor 1A or CDKN1A, is a human gene on chromosome 6 (location 6p21.2), that encodes a cyclin-dependent kinase) and gadd 45 (growth arrest and DNA-damage-inducible, alpha 45, a major breast cancer (BRCA1) target is the DNA damage-responsive gene GADD45) activation of peroxisome proliferative activated receptor gamma (PPARgamma) are involved in antitumor mechanism of these prostaglandins. At the low concentration, these prostaglandins exhibit physiological or pathological activity such as osteoblast calcification, promotion of colon cancer cell proliferation. One of the mechanisms of anti-cancer activity of prostaglandins, has been believed to be that these prostaglandins might have p53 like effect in cells lacking p53. (PMID: 7988663 , 11104898 )Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs) and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes) and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signaling pathways. |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- (13E,15S)-15-hydroxy-9-oxo-Prosta-10,13-dien-1-oate
- (13E,15S)-15-hydroxy-9-oxo-Prosta-10,13-dien-1-oic acid
- 15-Hydroxy-9-oxoprosta-10,13-dienoate
- 15-Hydroxy-9-oxoprosta-10,13-dienoic acid
- 15a-Hydroxy-9-ketoprosta-10,13-dienoate
- 15a-Hydroxy-9-ketoprosta-10,13-dienoic acid
- 15a-Hydroxy-9-oxo-10,13E-prostadienoate
- 15a-Hydroxy-9-oxo-10,13E-prostadienoic acid
- 2-(3-Hydroxy-1-octenyl)-5-oxo-3- cyclopentene-1-heptanoate
- 2-(3-Hydroxy-1-octenyl)-5-oxo-3- cyclopentene-1-heptanoic acid
- 2-(3-Hydroxy-1-octenyl)-5-oxo-3-Cyclopentene-1-heptanoate
- 2-(3-Hydroxy-1-octenyl)-5-oxo-3-Cyclopentene-1-heptanoic acid
- PGA1
- Prostaglandin A1
- Prostaglandin E1-217
|
| Chemical Formula |
C20H32O4 |
| Average Molecular Weight |
336.4657 |
| Monoisotopic Molecular Weight |
336.230059512 |
| IUPAC Name |
7-[(1R,2S)-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-3-en-1-yl]heptanoic acid |
| Traditional IUPAC Name |
prostaglandin A1 |
| CAS Registry Number |
14152-28-4 |
| SMILES |
CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O |
| InChI Identifier |
InChI=1S/C20H32O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h12-18,21H,2-11H2,1H3,(H,23,24)/b14-12+/t16-,17-,18+/m0/s1 |
| InChI Key |
BGKHCLZFGPIKKU-LDDQNKHRSA-N |
| Chemical Taxonomy |
| Kingdom |
Organic Compounds |
| Super Class |
Lipids |
| Class |
Eicosanoids |
| Sub Class |
Prostaglandins and related compounds |
| Other Descriptors |
- Aliphatic Homomonocyclic Compounds
- Carbocyclic Fatty Acids
- Keto Fatty Acids
- Organic Compounds
- Unsaturated Fatty Acids
|
| Substituents |
- Allyl Alcohol
- Carboxylic Acid
- Ketone
- Secondary Alcohol
|
| Direct Parent |
Prostaglandins and related compounds |
| Ontology |
| Status |
Detected and Quantified |
| Origin |
|
| Biofunction |
- Cell signaling
- Fuel and energy storage
- Fuel or energy source
- Membrane integrity/stability
- RNA component
|
| Application |
- Nutrients
- Stabilizers
- Surfactants and Emulsifiers
|
| Cellular locations |
- Extracellular
- Membrane (predicted from logP)
|
| Physical Properties |
| State |
Solid |
| Experimental Properties |
| Property |
Value |
Reference |
| Melting Point |
Not Available |
Not Available |
| Boiling Point |
Not Available |
Not Available |
| Water Solubility |
Not Available |
Not Available |
| LogP |
Not Available |
Not Available |
|
| Predicted Properties |
|
| Spectra |
|
Not Available
|
| Biological Properties |
| Cellular Locations |
- Extracellular
- Membrane (predicted from logP)
|
| Biofluid Locations |
|
| Tissue Location |
|
| Pathways |
Not Available
|
| Normal Concentrations |
|
| Blood |
Detected and Quantified |
|
0.000074 +/- 0.000048 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
|
| Abnormal Concentrations |
|
Not Available |
| Associated Disorders and Diseases |
| Disease References |
None |
| Associated OMIM IDs |
None |
| External Links |
| DrugBank ID |
Not Available |
| Phenol Explorer Compound ID |
Not Available |
| Phenol Explorer Metabolite ID |
Not Available |
| FoodDB ID |
FDB023040 |
| KNApSAcK ID |
Not Available |
| Chemspider ID |
4445196  |
| KEGG Compound ID |
C04685  |
| BioCyc ID |
CPD-1911  |
| BiGG ID |
Not Available |
| Wikipedia Link |
Not Available |
| NuGOwiki Link |
HMDB02656  |
| Metagene Link |
HMDB02656  |
| METLIN ID |
407  |
| PubChem Compound |
5281912  |
| PDB ID |
Not Available |
| ChEBI ID |
15545  |
| References |
| Synthesis Reference |
Pike, John E.; Lincoln, F. H.; Schneider, William Paul. Prostanoic acid chemistry. Journal of Organic Chemistry (1969), 34(11), 3552-7. |
| Material Safety Data Sheet (MSDS) |
Download (PDF)
|
| General References |
- Sasaki H, Fukushima M: Prostaglandins in the treatment of cancer. Anticancer Drugs. 1994 Apr;5(2):131-8.
Pubmed: 8049495
- Gueriguian FL: Prostaglandin-macromolecule interactions. I. Noncovalent binding of prostaglandins A1, E1, F2alpha, and E2 by human and bovine serum albumins. J Pharmacol Exp Ther. 1976 May;197(2):391-401.
Pubmed: 944773
- Montgomery RG, Patel NC, Lee JG: A comparison of the diuretic effects of prostaglandin A1, sodium ethacrynate, and placebo. Int J Clin Pharmacol Biopharm. 1975 Jul;12(1-2):102-8.
Pubmed: 1165130
- Aitokallio-Tallberg A, Viinikka L, Ylikorkala O: Urinary 6-keto-prostaglandin F1a in patients with gynaecological tumours. Cancer Lett. 1987 Feb;34(2):201-6.
Pubmed: 3545443
- Zhu Y, Gu ZL, Liang ZQ, Zhang HL, Qin ZH: Prostaglandin A1 inhibits increases in intracellular calcium concentration, TXA(2) production and platelet activation. Acta Pharmacol Sin. 2006 May;27(5):549-54.
Pubmed: 16626509
|